Rituximab biosimilar (mAbxience)

利妥昔单抗生物类似药 (mAbxience)

Report date: 2025/06/10 15:04:59

Base Information

Drug NameRituximab biosimilar (mAbxience)
Drug Alias NameNovexRituxikalVivaxxiaRTXM-83mAbx-02 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoproliferative DisordersAnemiaLymphoma, T-Cell +[17] 
Global Approved IndicationsLymphoma, Large B-Cell, Diffuse
Approved Indications in ChinaN/A
Original Approved Country/TerritoryArgentina
Original Approved Date2015/01/01
Country/TerritoryCanadaUnited StatesPuerto Rico +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMabxience Sa
China Registration ClassN/A

Develop Information

Active CompaniesMabxience SaNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesMabxience Research SL
Active IndicationsAnemiaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[10] 
Inactive IndicationsLymphoproliferative DisordersLymphoma, T-CellLymphoma, Mantle-Cell +[7] 

Other Information

ATC CodeL01XC02
Related LinksN/A